nirmatrelvir-ritonavir
Selected indexed studies
- Nirmatrelvir/ritonavir (Paxlovid®). (, 1994) [PMID:36378910]
- Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? (Biomed Pharmacother, 2023) [PMID:37018987]
- Nirmatrelvir/ritonavir (Paxlovid®). (, 1994) [PMID:36228054]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Nirmatrelvir Plus Ritonavir: First Approval. (2022) pubmed
- Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? (2023) pubmed
- Nirmatrelvir/ritonavir for COVID-19: an overview of systematic reviews. (2024) pubmed
- Nirmatrelvir and ritonavir. (2024) pubmed
- Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19. (2024) pubmed
- Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. (2023) pubmed
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. (2022) pubmed
- Paxlovid (nirmatrelvir/ritonavir). (2022) pubmed
- Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19. (2023) pubmed
- Nirmatrelvir-ritonavir for COVID-19. (2022) pubmed
- Nirmatrelvir/ritonavir (Paxlovid®). (1994) pubmed
- Nirmatrelvir/ritonavir (Paxlovid®). (1994) pubmed
- Nirmatrelvir-Ritonavir. (2026) pubmed
- Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir-A Literature Review. (2024) pubmed
- Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis. (2023) pubmed
- [Nirmatrelvir/ritonavir (Paxlovid®), a treatment for Covid-19]. (2022) pubmed